AAAAAA

   
Results: 1-15 |
Results: 15
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-Infected women
Authors: Cunningham, CK Wara, DW Kang, MH Fenton, T Hawkins, E McNamara, J Mofenson, L Duliege, AM Francis, D McFarland, EJ Borkowsky, W
Citation: Ck. Cunningham et al., Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-Infected women, CLIN INF D, 32(5), 2001, pp. 801-807
Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine
Authors: McFarland, EJ Borkowsky, W Fenton, T Wara, D McNamara, J Samson, P Kang, MH Mofenson, L Cunningham, C Duliege, AM Sinangil, F Spector, SA Jimenez, E Bryson, Y Burchett, S Frenkel, LM Yogev, R Gigliotti, F Luzuriaga, K Livingston, RA
Citation: Ej. Mcfarland et al., Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine, J INFEC DIS, 184(10), 2001, pp. 1331-1335
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
Authors: Belshe, RB Stevens, C Gorse, GJ Buchbinder, S Weinhold, K Sheppard, H Stablein, D Self, S McNamara, J Frey, S Flores, J Excler, JL Klein, M El Habib, R Duliege, AM Harro, C Corey, L Keefer, M Mulligan, M Wright, P Celum, C Judson, F Mayer, K McKirnan, D Marmor, M Woody, G
Citation: Rb. Belshe et al., Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers, J INFEC DIS, 183(9), 2001, pp. 1343-1352
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection
Authors: McElrath, MJ Corey, L Montefiori, D Wolff, M Schwartz, D Keefer, M Belshe, R Graham, BS Matthews, T Wright, P Gorse, G Dolin, R Berman, P Francis, D Duliege, AM Bolognesi, D Stablein, D Ketter, N Fast, P
Citation: Mj. Mcelrath et al., A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection, AIDS RES H, 16(9), 2000, pp. 907-919
Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients
Authors: Marshall, GS Li, MT Stout, GG Louthan, MV Duliege, AM Burke, RL Hunt, LA
Citation: Gs. Marshall et al., Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients, VIRAL IMMUN, 13(3), 2000, pp. 329-341
Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin
Authors: Drulak, MW Malinoski, FJ Fuller, SA Stewart, SS Hoskin, S Duliege, AM Sekulovich, R Burke, R Winston, S
Citation: Mw. Drulak et al., Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin, VIRAL IMMUN, 13(1), 2000, pp. 49-56
A phase I/II trial of HIVSF2 gp120/MF59 vaccine in seronegative Thais
Authors: Nitayaphan, S Khamboonruang, C Sirisophana, N Morgan, P Chiu, J Duliege, AM Chuenchitra, C Supapongse, T Rungruengthanakit, K deSouza, M Mascola, JR Boggio, K Ratto-Kim, S Markowitz, LE Birx, D Suriyanon, V McNeil, JG Brown, AE Michael, RA
Citation: S. Nitayaphan et al., A phase I/II trial of HIVSF2 gp120/MF59 vaccine in seronegative Thais, VACCINE, 18(15), 2000, pp. 1448-1455
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial
Authors: Davey, RT Murphy, RL Graziano, FM Boswell, SL Pavia, AT Cancio, M Nadler, JP Chaitt, DG Dewar, RL Sahner, DK Duliege, AM Capra, WB Leong, WP Giedlin, MA Lane, HC Kahn, JO
Citation: Rt. Davey et al., Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial, J AM MED A, 284(2), 2000, pp. 183-189
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Authors: Verrier, F Burda, S Belshe, R Duliege, AM Excler, JL Klein, M Zolla-Pazner, S
Citation: F. Verrier et al., A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates, J VIROLOGY, 74(21), 2000, pp. 10025-10033
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines
Authors: Borkowsky, W Wara, D Fenton, T McNamara, J Kang, MH Mofenson, L McFarland, E Cunningham, C Duliege, AM Francis, D Bryson, Y Burchett, S Spector, SA Frenkel, LM Starr, S Van Dyke, R Jimenez, E
Citation: W. Borkowsky et al., Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines, J INFEC DIS, 181(3), 2000, pp. 890-896
Effects of antigen dose and immunization regimens on antibody responses toa cytomegalovirus glycoprotein B subunit vaccine
Authors: Frey, SE Harrison, C Pass, RF Yang, E Boken, D Sekulovich, RE Percell, S Izu, AE Hirabayashi, S Burke, RL Duliege, AM
Citation: Se. Frey et al., Effects of antigen dose and immunization regimens on antibody responses toa cytomegalovirus glycoprotein B subunit vaccine, J INFEC DIS, 180(5), 1999, pp. 1700-1703
A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
Authors: Pass, RF Duliege, AM Boppana, S Sekulovich, R Percell, S Britt, W Burke, RL
Citation: Rf. Pass et al., A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant, J INFEC DIS, 180(4), 1999, pp. 970-975
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8(+) cytotoxic T lymphocyte responses in seronegative volunteers
Authors: Evans, TG Keefer, MC Weinhold, KJ Wolff, M Montefiori, D Gorse, GJ Graham, BS McElrath, MJ Clements-Mann, ML Mulligan, MJ Fast, P Walker, MC Excler, JL Duliege, AM Tartaglia, J
Citation: Tg. Evans et al., A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8(+) cytotoxic T lymphocyte responses in seronegative volunteers, J INFEC DIS, 180(2), 1999, pp. 290-298
Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children
Authors: Lambert, JS McNamara, J Katz, SL Fenton, T Kang, MH VanCott, TC Livingston, R Hawkins, E Moye, J Borkowsky, W Johnson, D Yogev, S Duliege, AM Francis, L Gershon, A Wara, D Martin, N Levin, F McSherry, F Smith, G
Citation: Js. Lambert et al., Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children, J ACQ IMM D, 19(5), 1998, pp. 451-461
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
Authors: Belshe, RB Gorse, GJ Mulligan, MJ Evans, TG Keefer, MC Excler, JL Duliege, AM Tartaglia, J Cox, WI McNamara, J Hwang, KL Bradney, A Montefiori, D Weinhold, KJ
Citation: Rb. Belshe et al., Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers, AIDS, 12(18), 1998, pp. 2407-2415
Risultati: 1-15 |